FLK-1-based minigene vaccines induce T cell-mediated suppression of angiogenesis and tumor protective immunity in syngeneic BALB/c mice

Vaccine

Volumn 25, Issue 8, 2007, Pages 1409-1415

  Luo, Yunping ^a   Markowitz, Dorothy ^a   Xiang, Rong ^a   Zhou, He ^a   Reisfeld, Ralph A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Anti angiogenesis; CTLs; Tumor vaccine

Indexed keywords

DNA VACCINE; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOMA; CANCER PREVENTION; CANCER THERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; FEMALE; GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR VASCULARIZATION;

ADMINISTRATION, ORAL; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COLONIC NEOPLASMS; ENDOTHELIAL CELLS; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; VACCINES, DNA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 33846204215     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.10.043     Document Type: Article

References (24)

1. Folkman J. Addressing tumor blood vessels. Nat Biotechnol 15 (1997) 510
2. Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS 79 (1997) 1-8
3. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
4. Folkman J. Tumor angiogenesis and tissue factor. Nat Med 2 (1996) 167-168
5. Augustin H.G. Antiangiogenic tumour therapy: will it work?. Trends Pharmacol Sci 19 (1998) 216-222
6. Heidenreich R., Kappel A., and Breier G. Tumor endothelium-specific transgene expression directed by vascular endothelial growth factor receptor-2 (FLK-1) promoter/enhancer sequences. Cancer Res 60 (2000) 6142-6147
7. Ferrara N. VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol 11 (2000) 617-624
8. Cross M.J., and Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 22 (2001) 201-207
9. Strawn L.M., McMahon G., App H., et al. FLK-1 as a target for tumor growth inhibition. Cancer Res 56 (1996) 3540-3545
10. Taraboletti G., and Margosio B. Antiangiogenic and antivascular therapy for cancer. Curr Opin Pharmacol 1 (2001) 378-384
11. Niethammer A.G., Xiang R., Becker J.C., et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 8 (2002) 1369-1375
12. Townsend A., and Bodmer H. Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 7 (1989) 601-624
13. Zhou H., Luo Y., Mizutani M., Mizutani N., Reisfeld R.A., and Xiang R. T cell-mediated suppression of angiogenesis results in tumor protective immunity. Blood 106 (2005) 2026-2032
14. Luo Y., Zhou H., Mizutani M., Mizutani N., Reisfeld R.A., and Xiang R. Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine. Proc Natl Acad Sci USA 100 (2003) 8850-8855
15. Zhou H., Luo Y., Mizutani M., et al. A novel transgenic mouse model for immunological evaluation of carcinoembryonic antigen-based DNA minigene vaccines. J Clin Invest 113 (2004) 1792-1798
16. Xiang R., Lode H.N., Chao T.H., et al. An autologous oral DNA vaccine protects against murine melanoma. Proc Natl Acad Sci USA 97 (2000) 5492-5497
17. Hansen J.E., Lund O., Tolstrup N., Gooley A.A., Williams K.L., and Brunak S. NetOglyc: prediction of mucin type O-glycosylation sites based on sequence context and surface accessibility. Glycoconj J 15 (1998) 115-130
18. Hicklin D.J., Marincola F.M., and Ferrone S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 5 (1999) 178-186
19. Ochsenbein A.F., Sierro S., Odermatt B., et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411 (2001) 1058-1064
20. Matthews W., Jordan C.T., Gavin M., Jenkins N.A., Copeland N.G., and Lemischka I.R. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc Natl Acad Sci USA 88 (1991) 9026-9030
21. Terman B.I., Carrion M.E., Kovacs E., Rasmussen B.A., Eddy R.L., and Shows T.B. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6 (1991) 1677-1683
22. Chen W., Yewdell J.W., Levine R.L., and Bennink J.R. Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants. J Exp Med 189 (1999) 1757-1764
23. +) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest 110 (2002) 1813-1822
24. Stuge T.B., Holmes S.P., Saharan S., et al. Diversity and recognition efficiency of T cell responses to cancer. PLoS Med 1 (2004) e28